Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression

Annals of Hematology - Germany
doi 10.1007/s00277-009-0846-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Megakaryocytes Harbour the Del(5q) Abnormality Despite Complete Clinical and Cytogenetic Remission Induced by Lenalidomide Treatment

British Journal of Haematology
Hematology
2018English

Diagnosis of Del(5q) MDS, 14 Years After JAK-2 Positive PV Appearance: Complete Remission of Both Diseases With Lenalidomide Monotherapy

Mediterranean Journal of Hematology and Infectious Diseases
Infectious DiseasesHematology
2016English

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica
Hematology
2008English

Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

An Evolution in Switching Therapy for Psoriasis Patients Who Fail to Meet Treatment Goals

Dermatologic Therapy
DermatologyMedicine
2015English

Clonal Heterogeneity in the 5q- Syndrome: P53 Expressing Progenitors Prevail During Lenalidomide Treatment and Expand at Disease Progression

Haematologica
Hematology
2009English

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2018English

Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results

American Journal of Hematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy